Biomind Labs Inc.
BMND
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.81% | 6.53% | -12.69% | -43.82% | -59.96% |
| Depreciation & Amortization | -33.33% | 0.00% | 33.33% | -4.35% | -66.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.33% | -10.72% | -40.83% | -59.20% | -71.74% |
| Operating Income | 3.33% | 10.72% | 40.83% | 59.20% | 71.74% |
| Income Before Tax | 83.86% | 94.28% | 85.07% | 78.16% | 51.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 83.86% | 94.28% | 85.07% | 78.16% | 51.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.86% | 94.28% | 85.07% | 78.16% | 51.50% |
| EBIT | 3.33% | 10.72% | 40.83% | 59.20% | 71.74% |
| EBITDA | 2.36% | 8.74% | 40.66% | 59.31% | 71.94% |
| EPS Basic | 84.04% | 93.40% | 84.13% | 77.36% | 51.55% |
| Normalized Basic EPS | 76.67% | 86.76% | 77.50% | 77.00% | 50.82% |
| EPS Diluted | 84.04% | 93.40% | 84.13% | 77.36% | 51.55% |
| Normalized Diluted EPS | 76.67% | 86.76% | 77.50% | 77.00% | 50.82% |
| Average Basic Shares Outstanding | 3.86% | 2.72% | 1.78% | 0.84% | -0.10% |
| Average Diluted Shares Outstanding | 3.86% | 2.72% | 1.78% | 0.84% | -0.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |